Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 10:56 AM
Ignite Modification Date:
2025-12-26 @ 10:56 AM
NCT ID:
NCT01170208
Eligibility Criteria:
Inclusion Criteria:
* GROUP I
* Have been clinically diagnosed with type-1 diabetes for at least 1-year
* Have an HgbA1c of 7.4% or higher
* Treated with short-acting insulin analog (i.e. HumaLog® Lispro, NovoLog® Aspart, Apidra® Glulisine) before each meal and only one injection of long-acting insulin analog Lantus® (Glargine), per day. Subjects must typically eat 3 meals per day. The total daily combined dose of the long-acting and short-acting insulin analogs must be 25 units or more. Patient must have been using the same insulin regimen for the previous 3-months
* Is currently using an insulin/carbohydrate ratio to decide how much short-acting insulin to take before meals and must be able to use the gram versus choice method of carbohydrate counting.
* GROUP II
* Have been clinically diagnosed with type-2 diabetes for at least 1-year
* Have an HgbA1c of 7.4% or higher
* Treated with short-acting insulin analog (i.e. HumaLog® Lispro, NovoLog® Aspart, Apidra® Glulisine) before each meal and only one injection of long-acting insulin analog Lantus® (Glargine) per day and. Subjects must typically eat 3 meals per day. The total daily combined dose of the long-acting and short-acting insulin analogs must be 25 units or more. Patient must have been using the same insulin regimen for the previous 3-months
* May be using other diabetes agent(s) at a stable dose for the last 3-months.
* GROUP III
* Have been clinically diagnosed with type-2 diabetes for at least 1-year
* Have an HgbA1c of 7.8% or higher
* Take twice daily biphasic Insulin (e.g. HumaLog® Mix 75/25, NovoLog® Mix 70/30) or premixed insulin (i.e. Humulin® 70/30, Novolin® 70/30, NPH/Regular insulin 70/30) with a total daily insulin dose of 25 units and have been using the same insulin regimen for the past 3-months
* May be using other diabetes agent(s) at a stable dose for the last 3-months.
Exclusion Criteria:
* Have a history of greater than 2 episodes of severe hypoglycemia in the past year, or have hypoglycemic unawareness when glucose levels are less than or equal to 50 mg/dl
* Have a significant physical, psychological, or cognitive impairment that would prohibit adherence to the protocol
* Have any severe cardiovascular disease including a history of congestive heart failure (New York Heart Association \[NYHA\] 3 or 4), unstable angina, myocardial infarction or stroke that occurred within the 6-months preceding enrollment
* Have known active anemia with a hemotocrit less than 25% in women or 30% in men
* Have known history of renal disease (e.g., serum creatinine level \>2.0 mg/dl or eGFR \< 30 ml/min)
* Have active cancer or cancer in the past 2-years (except non-melanoma skin cancer
* Have history of significant liver disease including cirrhosis or elevated liver enzymes (e.g., AST and ALT greater than 3 times the upper limit of normal values)
* Have a body mass index (BMI) \> 45 kg/m2; and/or
* Are pregnant, plan to become pregnant during the study period, or are breastfeeding.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
21 Years
Maximum Age:
70 Years
Study:
NCT01170208
Study Brief:
Protocol Section:
NCT01170208